Cargando…
Immune thrombotic thrombocytopenic purpura: Personalized therapy using ADAMTS‐13 activity and autoantibodies
Recently, treatment of immune‐mediated thrombotic thrombocytopenic purpura (ITTP) has changed with the advent of caplacizumab in clinical practice. The International Working Group (IWG) has recently integrated the ADAMTS‐13 activity/autoantibody monitoring in consensus outcome definitions. We report...
Autores principales: | Palandri, Francesca, Di Pietro, Christian, Ricci, Francesca, Tazzari, Pier Luigi, Randi, Vanda, Bartoletti, Daniela, Cavo, Michele, Vianelli, Nicola, Auteri, Giuseppe |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
John Wiley and Sons Inc.
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660682/ https://www.ncbi.nlm.nih.gov/pubmed/34938937 http://dx.doi.org/10.1002/rth2.12606 |
Ejemplares similares
-
Pathogenicity of Anti-ADAMTS13 Autoantibodies in Acquired Thrombotic Thrombocytopenic Purpura()
por: Thomas, Mari R., et al.
Publicado: (2015) -
Recombinant ADAMTS 13 in thrombotic thrombocytopenic purpura
por: Scully, Marie, et al.
Publicado: (2017) -
Modifying ADAMTS13 to modulate binding of pathogenic autoantibodies of patients with acquired thrombotic thrombocytopenic purpura
por: Graça, Nuno A. G., et al.
Publicado: (2019) -
ADAMTS13 and Non-ADAMTS13 Biomarkers in Immune-Mediated Thrombotic Thrombocytopenic Purpura
por: Bonnez, Quintijn, et al.
Publicado: (2023) -
Generation and validation of small ADAMTS13 fragments for epitope mapping of anti‐ADAMTS13 autoantibodies in immune‐mediated thrombotic thrombocytopenic purpura
por: Kangro, Kadri, et al.
Publicado: (2020)